“The approval of Dexcom G7 15 Day marks another major innovation for Dexcom,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “By listening to the needs of our users, ...

CEO Kevin Sayer highlighted 14% organic revenue growth for Q1 2025, marking the second consecutive quarter of reaccelerating growth. He credited strong category demand, access wins, and effective ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

Secure digital identity, interoperable payments, and open-source security are becoming essential to deliver climate ...